ME Therapeutics Holding (FRA:Q9T) ROCE % : -79.65% (As of Aug. 2024)

View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ME Therapeutics Holding's annualized ROCE % for the quarter that ended in Aug. 2024 was -79.65%.

ME Therapeutics Holding ROCE % Historical Data

The historical data trend for ME Therapeutics Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding ROCE % Chart

ME Therapeutics Holding Annual Data

Trend

Aug22

Aug23

Aug24

ROCE %

-2,944.19

-128.74

ME Therapeutics Holding Quarterly Data
	Aug22	Dec22	May23	Aug23	Nov23	Feb24	May24	Aug24
ROCE %	Get a 7-Day Free Trial			-2,252.81	-297.58	-65.22	-132.02	-79.65

ME Therapeutics Holding ROCE % Calculation

ME Therapeutics Holding's annualized ROCE % for the fiscal year that ended in Aug. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2024 )		(A: Aug. 2023 )		(A: Aug. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2024 )		(A: Aug. 2023 )		(A: Aug. 2024 )
	=	-0.86	/	( ( (0.457 - 0.101)	+	(1.022 - 0.042) )	/ 2 )
	=	-0.86	/	( (0.356	+	0.98)	/ 2 )
	=	-0.86	/	0.668
	=	-128.74 %

ME Therapeutics Holding's ROCE % of for the quarter that ended in Aug. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Aug. 2024 )		(Q: May. 2024 )		(Q: Aug. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Aug. 2024 )		(Q: May. 2024 )		(Q: Aug. 2024 )
	=	-0.828	/	( ( (1.131 - 0.032)	+	(1.022 - 0.042) )	/ 2 )
	=	-0.828	/	( ( 1.099	+	0.98 )	/ 2 )
	=	-0.828	/	1.0395
	=	-79.65 %

(1) Note: The EBIT data used here is four times the quarterly (Aug. 2024) EBIT data.

ME Therapeutics Holding (FRA:Q9T) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ME Therapeutics Holding ROCE % Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (FRA:Q9T) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

METX:Canada

Address

177 Robson St., Vancouver, BC, CAN, V6B 0N3

Website

https://www.metherapeutics.com

ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding Headlines

No Headlines